🩹 Shingles Vaccine Reactogenicity Timeline Simulator

Injection Administered — Adjuvant-Driven Immune Activation

Shingrix triggers a deliberately strong innate immune response.

• AS01B: Adjuvant system (liposomal saponin adjuvant)
• gE: Antigen (recombinant VZV surface protein)
• >90%: Efficacy vs shingles (ages 50 and older)
• <1 day: Onset of reaction (immune activation begins fast)

AS01B adjuvant system

Adjuvant deliberately provokes a strong, transient inflammatory response.

Why reactogenicity is expected

Stronger local reaction correlates with stronger long-term protection.

Recombinant gE antigen

Glycoprotein E antigen primes T cells against dormant VZV.

Day 1 — Injection-Site Pain, Redness & Swelling Peak

Local pain and swelling peak within twenty-four hours.

• ~78%: Any local pain (of recipients)
• ~9%: Severe pain (limits arm movement)
• ~34%: Visible redness (erythema at injection site)
• Day 1: Peak pain day (sharpest local discomfort)

Injection-site pain

Most recipients report moderate to severe arm soreness.

Redness and swelling

Localized erythema and edema surround the injection site.

Local symptom prevalence

Roughly eight in ten recipients experience local reactions.

Day 1–2 — Fatigue, Myalgia, Headache & Fever Peak

Systemic symptoms crest as cytokines circulate body-wide.

• ~57%: Fatigue (systemic tiredness reported)
• ~46%: Myalgia (muscle aches reported)
• ~35%: Headache (mild to moderate)
• ~11%: Fever (above 37.5°C)

Fatigue and myalgia

Whole-body tiredness and muscle aches often peak together.

Headache and fever

Roughly one in ten recipients develop a mild fever.

Cytokine circulation

Circulating interleukins drive systemic flu-like symptoms transiently.

Day 3 — Acute Inflammation Subsides

Day three marks the inflammatory turning point.

• 2–3 days: Symptom duration (typical total duration)
• ~70%: Feeling better by day 3 (of recipients)
• <1 day: Activity impact (missed on average)
• <17%: Severe reaction rate (grade 3, any symptom)

Inflammation subsides

Acute inflammatory mediators clear steadily from tissue.

Pain and swelling fade

Injection-site discomfort noticeably eases by day three.

Energy returns

Fatigue and myalgia continue declining toward baseline.

Day 4–7 — Resolution & the Second Dose

Most side effects vanish before a possible second dose.

• ~Day 7: Full resolution (nearly all symptoms gone)
• 2–6 mo: Dose interval (recommended spacing)
• Slightly higher: Dose 2 reactogenicity (than dose one)
• >90%: Overall efficacy (sustained past 4 years)

Full resolution

Nearly all reactogenicity resolves within about a week.

Second dose timing

Dose two follows two to six months later.

Slightly stronger second reaction

Second dose often produces marginally stronger reactogenicity.